Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1-cis-2-(alpha-dimethylamino-m-hydroxybenzyl)cyclohexanol.hcl
2. Ciramadol
3. Ciramadol, (1r-1alpha(r*),2alpha)-isomer
4. Phenol, 3-((dimethylamino)(2-hydroxycyclohexyl)methyl)-, Hydrochloride, (1alpha(r*),2alpha)-(-)-
5. Wy-15,705
1. Ciramadol Hcl
2. Ciradol
3. Ciramadol Hydrochloride [usan]
4. 63323-46-6
5. Wy-15,705 Hcl
6. 090xo8449j
7. Ciramadol Hydrochloride (usan)
8. 3-[(r)-dimethylamino-[(1r,2r)-2-hydroxycyclohexyl]methyl]phenol;hydrochloride
9. Wy 15705 Hydrochloride
10. Unii-090xo8449j
11. Einecs 264-099-4
12. Schembl121279
13. Chembl2104041
14. Dtxsid40979443
15. Wy-15705 Hydrochloride
16. Wy-15,705 Hydrochloride
17. Ciramadol Hydrochloride [mi]
18. (-)-(1r,2r)-2-((r)-alpha-(dimethylamino)-m-hydroxybenzyl)cyclohexanol Hydrochloride
19. D03524
20. Q27236440
21. 3-[(dimethylamino)(2-hydroxycyclohexyl)methyl]phenol--hydrogen Chloride (1/1)
22. (-)-(1r,2r)-2-((r)-.alpha.-(dimethylamino)-m-hydroxybenzyl)cyclohexanol Hydrochloride
23. (1r-(1alpha(r*),2alpha)-(3-hydroxy-(alpha-(2-hydroxycyclohexyl)benzyl)dimethylammonium Chloride
24. Phenol, 3-((dimethylamino)(2-hydroxycyclohexyl)methyl)-, Hydrochloride, (1r-(1.alpha.(r*),2.alpha.))- (-)-
25. Phenol, 3-((dimethylamino)(2-hydroxycyclohexyl)methyl)-, Hydrochloride, (1r-(1alpha(r*),2alpha))- (-)-
| Molecular Weight | 285.81 g/mol |
|---|---|
| Molecular Formula | C15H24ClNO2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 285.1495567 g/mol |
| Monoisotopic Mass | 285.1495567 g/mol |
| Topological Polar Surface Area | 43.7 Ų |
| Heavy Atom Count | 19 |
| Formal Charge | 0 |
| Complexity | 257 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Analgesics
Compounds capable of relieving pain without the loss of CONSCIOUSNESS. (See all compounds classified as Analgesics.)
ABOUT THIS PAGE
A Ciramadol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ciramadol, including repackagers and relabelers. The FDA regulates Ciramadol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ciramadol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ciramadol supplier is an individual or a company that provides Ciramadol active pharmaceutical ingredient (API) or Ciramadol finished formulations upon request. The Ciramadol suppliers may include Ciramadol API manufacturers, exporters, distributors and traders.
click here to find a list of Ciramadol suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ciramadol DMF (Drug Master File) is a document detailing the whole manufacturing process of Ciramadol active pharmaceutical ingredient (API) in detail. Different forms of Ciramadol DMFs exist exist since differing nations have different regulations, such as Ciramadol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ciramadol DMF submitted to regulatory agencies in the US is known as a USDMF. Ciramadol USDMF includes data on Ciramadol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ciramadol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ciramadol suppliers with USDMF on PharmaCompass.
Ciramadol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ciramadol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ciramadol GMP manufacturer or Ciramadol GMP API supplier for your needs.
A Ciramadol CoA (Certificate of Analysis) is a formal document that attests to Ciramadol's compliance with Ciramadol specifications and serves as a tool for batch-level quality control.
Ciramadol CoA mostly includes findings from lab analyses of a specific batch. For each Ciramadol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ciramadol may be tested according to a variety of international standards, such as European Pharmacopoeia (Ciramadol EP), Ciramadol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ciramadol USP).
LOOKING FOR A SUPPLIER?
